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Key points 
 1. Serum cytokine profiling predicts disease transformation in myeloproliferative neoplasms 
independently of clinical and genomic variables 
 2. Identification of two potential biomarkers for disease transformation in patients with 
essential thrombocythemia (one at diagnosis and one longitudinal) 
 
Abstract 
Myeloproliferative neoplasms (MPNs) are characterized by deregulation of mature blood cell 
production and increased risk of myelofibrosis (MF) and leukemic transformation. Numerous 
driver mutations have been identified, but substantial disease heterogeneity remains unexplained, 
implying the involvement of additional as yet unidentified factors. The inflammatory 
microenvironment has recently attracted attention as a crucial factor in MPN biology, in particular 
whether inflammatory cytokines and chemokines contribute to disease establishment or 
progression.  Here we present a large-scale study of cytokine profiles in more than 400 MPN 
patients and identify an Essential Thrombocythemia (ET)-specific inflammatory cytokine 
signature consisting of Eotaxin, GRO-α, and EGF. Levels of two of these markers (GRO-α and 
EGF) in ET patients were associated with disease transformation in initial sample collection 
(GRO-α) or longitudinal sampling (EGF). In ET patients with extensive genomic profiling data 
(n=183) cytokine levels added significant prognostic value for predicting transformation from ET 
to MF. Furthermore, CD56
+
CD14
+
 pro-inflammatory monocytes were identified as a novel source 
of increased GRO-α levels.  These data implicate the immune cell microenvironment as a 
significant player in ET disease evolution and illustrate the utility of cytokines as potential 
biomarkers for reaching beyond genomic classification for disease stratification and monitoring. 
(195 words) 
?  
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Introduction 
Leukemia is typically associated with the step-wise acquisition of mutations, and large-
scale genomic profiling efforts have identified the major driver mutations in hematological 
malignancies
1,2
.  Despite these efforts, significant disease heterogeneity persists across patients 
with identical driver mutation profiles. Comparatively little is known about the cellular 
environment in which these cells reside and what impact neighboring cells, or the molecules they 
secrete, might have on disease evolution.   A powerful disease model for studying the early stages 
of tumorigenesis is the chronic myeloproliferative neoplasms (MPNs), where a fraction of patients 
progresses to either develop bone marrow fibrosis or, in the most severe cases, transform to acute 
leukemia. 
Key studies emerging from the field of pre-leukemic diseases and leukemia suggest that 
the inflammatory microenvironment plays a significant role in disease establishment and 
maintenance
3Ð5
. Recent clinical and biological findings point to a role for chronic inflammation as 
a key extrinsic factor, driving aspects of Philadelphia Chromosome negative myeloproliferative 
neoplasm (MPN) pathogenesis and progression
6Ð9
.  
The role that cytokines play as regulators of normal hematopoiesis is widely recognized, 
and the balance between self-renewal and differentiation in hematopoietic stem cells (HSCs) is 
tightly regulated by micro-environmental factors both in steady-state and during stress
10
. 
Deregulation of inflammatory cytokines in MPN patients has been reported in a number of 
previous studies
11Ð17
 and IL-8 and IL2R levels were associated with overall survival in the most 
severe MPN subtype myelofibrosis (MF)
12
. However, the vast majority of studies did not profile 
large numbers of the less severe subtype essential thrombocythemia (ET) patients and samples 
were often from a single static timepoint.  
Here, we undertake a comprehensive serum cytokine profile of more than 400 MPN 
patient samples. Cytokine data and longitudinal sampling were integrated with clinical and genetic 
information to determine whether potential biomarkers for adverse prognosis or disease 
monitoring could be identified.  Levels of two such markers, GRO-α and EGF, were identified as 
indicators of transformation-free survival in pre-treatment and longitudinal samples respectively, 
adding significant prognostic information beyond genetic profiling. 
 
Methods 
Patient samples  
The study included three groups of Philadelphia chromosome negative MPN patients: A) 
Cambridge cohort (n=291 patients), B) Swiss cohort (n=204 patients), and C) a selected PT-1 
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cohort (n=122 patients) enriched for MF and AML transformation events (Supplemental 
Appendix 1).  Patients from UK cohorts (A and C) were diagnosed according to the British 
Committee for Standards in Haematology (BCSH) guidelines
18
. Diagnosis in the Swiss cohort was 
established according to the revised criteria of the World Health Organization
19
.  UK patient 
samples were obtained under local ethics approval (Cambridge and Eastern Region Ethics 
Committee), or as part of the UK Medical Research Council PT-1 trial
20Ð23
. For the Swiss cohort, 
samples and clinical data were obtained at the study centre in Basel (Switzerland), and approved 
by the local Ethics Commitees (Ethik Kommission Beider Basel). Written informed consent was 
obtained from all patients in accordance with the Declaration of Helsinki.  For local Cambridge 
patients, samples were taken at the time of the initial patient visit on referral to the specialist MPN 
clinic.  For the PT-1 patient cohort, 36% of patients had their samples collected before receiving 
any cytoreductive therapy and >80% of patients were sampled within the first 30 days 
(Supplemental Appendix 1). From the UK patient cohorts, targeted sequencing of the coding 
regions of 33 recurrently mutated genes was available for 239 patients (n=117 from Cambridge 
cohort, n=122 from PT1 cohort)
24
. Longitudinal studies included repeat samples from UK patient 
cohorts (n=81). Cytoreductive treatment information was available in PT1 cohort patients and 
included in multivariate analyses. Baseline bone marrow fibrosis data was available for a subset of 
patients (n=44). 
Patient serum cytokine profiling  
Blood was collected in Becton Dickenson (BD) Vacutainer tubes or S-Monovette Z Gel clot 
activator tubes (Sarstedt). After clot formation and centrifugation, serum aliquots were stored at -
80¡C or in liquid nitrogen (Cambridge Blood Stem Cell Biobank). An initial 38-plex panel 
(Milliplex HCYTOMAG-60K-PX38) was run on 185 MPN patients and 14 healthy controls. A 
10-plex custom assay (IP-10, IL-8, EGF, Eotaxin, TGF-α, IFN-γ, GRO-α, IL1-RA, TNF-α, IL-6) 
was designed to profile a further 106 MPN cases (total n=291), as well as an additional 122 ET 
patients for biomarker validation (PT-1 cohort). Each immunoassay was completed using 25µL 
serum (undiluted) and was performed according to the manufacturer's protocol, and protein 
quantification was undertaken to ensure that cytokine levels were not skewed by overall protein 
content (Supplementary Table 1). Plates were run on Luminex xMAP (Luminex Corp., Austin, 
TX) and cytokine concentrations were determined by xPONENT software (Luminex), using 
values derived from the known reference concentrations.  Total protein quantification was 
undertaken, and no cytokines were significantly correlated with total protein amounts (data not 
shown). Serum cytokine profiling (25 cytokines) in the Swiss cohort was performed using the 
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Meso Scale Discovery Platform (Rockville, Maryland, USA) according to the manufacturerÕs 
instructions.  
Intracellular flow cytometry 
Fresh peripheral blood samples were collected in Lithium Heparin tubes (AddenbrookeÕs MPN 
Clinic), and mononuclear cells (MNCs) were isolated by density gradient centrifugation 
(Lymphoprep, Axis-Shield, Oslo, Norway). MNCs were plated at 2-5x10
6
 cells/mL in RPMI 
(Sigma) supplemented with 10% fetal calf serum plus secretion inhibitor (GolgiSTOP, BD 
Biosciences (BD), 0.6µL/well) and were stimulated for 4h with 100 ng/mL lipopolysaccharide 
(LPS, Sigma). After stimulation, cells were washed, treated with Fc-Receptor Blocking (BD 
Biosciences) and stained for cell surface markers CD45/V450 (HI30, BD), CD3/APC, CD14/PE-
Cy7 (M5E2, BD or BioLegend), CD15 BV605 (W6D3, BD), CD56/BV711 (NCAM16.2, BD) and 
Zombie Aqua (Biolegend) for live/dead cell discrimination. Cells were washed, fixed and 
permeabilized (Fixation/Permeabilization solution, BD), washed in Perm/Wash buffer (BD) before 
intracellular stain using GRO-α/PE (#20326, R&D). Samples were run on a BD Fortessa and 
analyzed in FlowJo10.  After gating for CD45
+
 live singlets (using FSC-A, SSC-A, FSC-H), total 
GRO-α
+
 cells were gated as percentage of total live MNCs using the unstimulated level in heathy 
control samples as threshold for positivity. The following MNC subsets were gated on mature cell 
markers: Monocytes (CD14
+
CD15
-
), T-cells (CD3
+
CD56
-
CD14
-
CD15
-
CD19
-
), NK-cells (CD3
-
CD56
+
CD14
-
 CD15
-
CD19
-
), and NKT-cells (CD3
+
CD56
+
CD14
-
CD15
-
CD19
-
). The proportion of 
MNC subsets producing GRO-α was analyzed as the percentages of monocytes (CD56
-
 and 
CD56
+ 
subsets), T-, NK-, and NKT-cells of total GRO-α
+
 cells. 
 
Statistical analysis  
Kruskall-Wallis and Mann-Whitney U-tests (GraphPad Prism7 and R) were used for comparison 
of cytokine concentrations between patient subgroups. FisherÕs Exact test was used for 
proportional MNC subtype analyses of GRO-α flow cytometry data. Kaplan-Meier and Cox 
proportional hazards modelling (for time-to-event analyses), Random Forest, and Mixed Effects 
Modelling were done in R (v3.2.2). The R packages used were ggplot2 (v2.2.1), randomForest 
(v4.6-12), rms (vs5.1-0), survival (v2.40-1) and lme4 (v1.1-12). Multivariate analyses included: 
age at diagnosis, sex, white cell and platelet counts, and where available and specifically stated in 
sub-group analyses: mutation status (0/1) for recurrently mutated genes (JAK2, CALR, MPL, 
TET2, DNMT3A, ASXL1, SRSF2, U2AF1, IDH2, SF3B1 and CBL), reticulin grade at diagnosis 
and length of treatment on anagrelide or hydroxycarbamide. These 11 genes all occurred in >2% 
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of patients and have been previously implicated in MPN pathogenesis. A spreadsheet of all patient 
data analyzed can be found as Supplemental Appendix 1. 
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Results  
MPNs have disease-specific patterns of inflammatory molecules 
Thirty-eight inflammatory molecules were quantified in serum from an initial 185 patients 
from the Cambridge cohort (104 ET, 52 polycythemia vera (PV) and 29 primary myelofibrosis 
(PMF) (Figure 1A), to identify those that were most discriminatory for MPN subtype 
(Supplemental Figure 1A). When disease subtypes were considered as single entities against each 
other (and normal controls), a number of cytokines were significantly altered and showed strong 
disease specificity. Each of EGF, Eotaxin, GRO-α, TGF-α, IL-1RA, TNF-α, IL-6, IL-8, IP-10 and 
IFN-γ, were significantly different for at least one MPN subtype (Supplemental Figure 1B) or 
associated with decreased overall survival (IL-6, p=0.01). These informative cytokines were 
combined in a custom 10-plex array used for all further studies. 
To further investigate these findings, we extended the Cambridge cohort to a total of 291 
patient patients (146 ET, 94 PV, 51 PMF) (Figure 1B) for analyses using the custom 10-plex 
array. Group comparison for the individual cytokines and principal component analysis of the full 
dataset further confirmed distinct inflammatory cytokine networks associated with the ET, PV or 
PMF subtypes (Figure 1C). PMF was associated with increased levels of TNF-α, IP-10 and IL-8 
(Supplemental Figure 2A), which is consistent with previous studies
12
 and these findings were 
reinforced by results from a separate Swiss cohort (n=204 patients, n=24 controls) analyzed with a 
different screening platform (Supplemental Figure 2B).  
Comprehensive data on mutation status for genes commonly mutated in MPNs, as well as 
recurrent chromosomal abnormalities (including JAK2, CALR, MPL, TET2, DNMT3A, ASXL1, 
EZH2, SRSF2, 9pUPD and del(20q)), was available for a majority of patients
24
. After correction for 
diagnosis, age and sex, surprisingly few differences in cytokine levels were observed across patients 
based on mutational status alone, suggesting that micro-environmental heterogeneity was not 
dominantly instructed by a particular genetic lesion or combination of lesions. The single exception 
was IP-10, which showed positive correlation with JAK2V617F variant allele fraction in ET 
(p=0.023), PV (p=0.0061) and MF (p=0.027) patients.  
Previous studies have concluded that relatively lower levels of pro-inflammatory 
cytokines/chemokines are present in patients with ET compared to those with PV and MF 
patients
86
, although these studies had very few ET patients (n=5, n=15, and n=21)
13,14,16 
compared 
to our cohort of 146 ET patients, and/or studied a smaller panel of cytokines.  Counter to this 
notion, we found that GRO-α (CXCL1) levels were markedly raised in ET patients compared to 
other MPNs, while EGF and Eotaxin (CCL11) were higher in both ET and PV compared to MF 
patients (Figure 2A). These findings were confirmed by multivariate analysis (ANOVA) that 
included age and sex.   
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CD56
+
CD14
+
 pro-inflammatory monocytes drive over-production of GRO-α 
To further examine the different disease-specific microenvironments, we next surveyed various 
mature blood cell types (T-, NK-, NKT-cells, and monocytes) by intra-cellular flow cytometry to 
determine the cellular origin of GRO-α production in patients (Supplemental Figure 3).  Following 
LPS stimulation, GRO-α production in total PB MNCs ranged from 1-8% (Figure 2B) with a 
proportion of ET patients having substantially higher numbers of GRO-α producing cells.  
Monocytes were the predominant producer of GRO-α in all patient samples, with GRO-
α
+
CD56
+
CD14
+
 monocytes being significantly increased in ET patient samples compared to 
normal controls (p=0.008, Figure 2C). CD56
+
CD14
+
 monocytes are known to be a pro-
inflammatory subset of monocytes
25
, increased levels of which have been found in patients with 
solid tumors and hematological malignancies
26
.  These data suggest a role for CD56
+
CD14
+
 
monocytes in creating a high GRO-α environment which may in turn be a driver of MPN disease 
evolution. Hyperactive monocytes have also been implicated in MF patients, where increased 
constitutive production of cytokines included TNF-α, IL-10 and TGF- § 
27
. 
 
GRO-α levels are predictive of transformation in ET patients 
Comprehensive long-term clinical outcome data was available for 182 of the 291 patients in the 
original Cambridge cohort and these data were used to determine whether cytokine levels might 
be useful as predictive prognostic biomarkers.  Of these, data in ET patients (n=116), showed that 
high levels of GRO-α correlated with an increased risk of transformation from ET to MF (Cox 
proportional hazards modeling, p=0.004) (Figure 3A). However, since this ET cohort only had 8 
transformation events (6 secondary MF (sMF), 2 sAML), we extended our 10-plex serum cytokine 
analysis to a further 122 ET patients from the PT1 study
20Ð22
. From the >1200 patients in the PT-1 
trial, we selected a cohort that was highly enriched for patients with transformation events (26 
sAMLs, 30 sMFs, 69 deaths) to directly address the question of whether initial GRO-α levels 
could predict transformation. The PT1 cohort had genomic and clinical data was available with a 
median of 11.7 years of follow-up (range 2 months to 43 years from diagnosis). In this dataset, the 
correlation of high GRO-α levels with risk of ET to sMF transformation was confirmed (p=0.01, 
Figure 3B), although GRO-α levels did not associate with sAML transformation (data not shown). 
Baseline BM fibrosis grade, available for 44 patients, showed no significant association with 
GRO-α level (p=0.83), and the predictive value of GRO-α remained significant after inclusion of 
fibrosis grade as a covariate in this set of patients (p=0.005). Fourteen patients with low or 
intermediate GRO levels together with reticulin grade 0-1 had no MF transformation, compared 
with transformation occurring in half of the remaining 30 patients with either high GRO or 
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fibrosis grade 2-3 at baseline. Notably, diagnostic PMF samples did not have elevated GRO-α 
levels, suggesting that high levels are predictive of future chronic phase transformation rather than 
a hallmark feature of myelofibrosis.  
 
Cytokine profiling improves on genomics for predicting transformation-free survival 
We next assessed adding cytokine quantification to prognostic models utilizing demographic and 
clinical data alone, and those additionally incorporating genomic variables (Figure 3C). Here we 
assessed age, sex, levels of all 10 cytokines and the presence or absence of 33 genetic mutations 
for their capacity to predict transformation to sMF or sAML and survival in MPN patients. Firstly, 
this analysis confirmed a recently published study showing that comprehensive genomic 
characterization can improve the prediction for disease transformation
24
. Secondly, inclusion of 
cytokine levels improved the performance of the prognostic model, as assessed by the 
Concordance-statistic for goodness of fit (Figure 3D). Stepwise variable selection identified a 
prognostic model that included age, presence/absence of U2AF1 or SRSF2 mutations, GRO-α, IL-
8 (p-value <0.01) and IP-10 (p-value=0.12) levels (Figure 3E). 
 
Longitudinal monitoring of EGF levels predicts transformation events 
We extended our study to longitudinal samples (n=81) to determine whether any of the 
chronic phase markers (EGF, Eotaxin, and GRO-α) might be useful for monitoring disease for risk 
of subsequent transformation. Here it was observed that the rate of change in EGF levels strongly 
correlated with transformation risk (p-value=0.008), with the vast majority of transformations 
(~80%) observed in patients whose EGF levels decreased over time (Figure 4A and 4B), where 
stability was defined as an absolute rate of change of <8pg/mL per year.  Compared to patients 
with stable or increasing EGF levels, there was a 4.3-fold (95% confidence interval 1.7 - 10.9) 
increased likelihood of transformation to sMF or sAML when EGF levels dropped over the course 
of the longitudinal sampling. The association between decreasing EGF levels and risk of 
myelofibrotic transformation remained significant after correction for baseline reticulin grade and 
treatment with anagrelide or hydroxycarbamide (p=0.02). This indicates the potential utility of 
monitoring EGF levels during the course of disease adding a dynamic measurement of disease 
evolution which would reach beyond traditional binary assessments of mutant/non-mutant that are 
common with genomic profiling. 
 
 
Discussion 
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Recent studies have explored the pivotal role for the microenvironment in the 
establishment and maintenance of myeloid malignancies
3,28Ð30
. High levels of inflammatory 
cytokines have been observed in myelofibrosis
11Ð13
, MDS
31,32
, and AML
32
 and IFN-α is an 
established treatment in the management of myeloid malignancies
33
. In this study, serum cytokine 
profiling spanning MPN subtypes identified 10 cytokines that associate with disease subtype 
and/or disease severity.  Moreover, prognostic modelling demonstrated that measuring cytokines 
could complement clinical and genomic information for the prediction of transformation-free 
survival, suggesting they may be useful for disease monitoring and assessment.   
Our data identify a small collection of inflammatory cytokines (GRO-α, EGF, and Eotaxin) 
that are elevated in chronic phase MPNs. Previous ET patient data concluded that relatively low 
levels of chemokines, pro- or anti-inflammatory cytokines, or hematopoietic growth factors were 
present in patients with ET compared to those with PV and MF
8
. However, these studies often had 
very few patients (n=5 in Ho et al. 2007
14
, n=21 in Pourcelot et al. 2014
16
, n=15 in Boissinot et al. 
2011
13
) and only one of these studies measured GRO-α, EGF, or Eotaxin levels
14
 with no 
significant changes observed, likely due to the small number of ET patients sampled (n=5). Our 
study of all MPN subtypes comprising 146 ET patients, was the first to be sufficiently powered to 
identify ET-specific differences in GRO-α, EGF, and Eotaxin levels and clearly demonstrates their 
dysregulation in ET patients. 
Surveying genetic mutations in myeloid malignancies has become increasingly utilized for 
predicting outcomes
24,34
, but mutations cannot fully explain disease heterogeneity. This could be 
due to different stages of disease evolution, a different cell of origin
35
, different sized mutant 
clones
36
, different orders of mutation acquisition
37
, or other factors not yet tracked. Here we 
demonstrate that cytokine measurements have substantial prognostic value for predicting 
transformation in addition to age, demographics and comprehensive genomics. Specifically, single 
time-point cytokine measurements demonstrated predictive utility, with high levels of GRO-α being 
predictive of MF transformation in both the initial and validation cohorts, and decreasing EGF 
levels over time predicting for transformation in longitudinal sampling. Of particular interest, 
measuring longitudinal changes in EGF levels goes beyond the traditional binary assessment of 
mutant/non-mutant status that is often done with genomic profiling, although it would require a 
prospective trial with MPN and healthy controls that has set analysis timepoints and tests the utility 
of an 8pg/mL/year rate of change. 
Altered cytokine levels in MPN patients might derive from hematopoietic (clonal and/or 
non-clonal) or non-hematopoietic cell sources
38
. One potential mechanism is the clonal expansion 
of megakaryocytes and monocytes associated with MPNs. Increases in cell number might translate 
into higher levels of specific cytokines, potentially driving increased angiogenesis or fibroblast 
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differentiation/recruitment with consequent bone marrow fibrosis
39,40
. GRO-α has been associated 
with high platelet counts
41
 and has been previously implicated in vascular disease
42,43
 and we 
identify CD56
+
CD14
+
 monocytes as a potential source of GRO-α. Also of interest, other groups 
have demonstrated that loss-of-function TET2 mutations associate with macrophage-mediated 
inflammation
44
, cardiovascular disease
45,46
 and co-operate with microbial infections to drive 
myeloproliferation
47
. It is also possible that additional treatment agents (immunosuppressants, 
steroids, etc) could alter cytokine levels. Clearly, the number of variables relevant to disease 
pathogenesis extends beyond genetic changes in an individual, indicating a strong need to generate 
comprehensive biological, genetic, and clinical datasets. Such datasets will be essential to define 
which inflammatory mediators play a dominant role in MPNs and detail how MPN-associated 
inflammatory cytokines might contribute to disease evolution. 
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Figure legends 
 
Figure 1. Serum cytokine profiling identifies distinct cytokine networks in MPNs. 
A) Overview of serum cytokine screen. Initially levels of 38 cytokines were assessed in serum 
samples from MPN patients by multiplexed ELISA. Following data analysis, 10 cytokines were 
selected for their ability to track with disease subtypes, disease severity or overall survival.  
B) Summary information for patient groups. Median follow-up time is displayed in years with 
minimum/maximum follow-up indicated in parenthesis. Abbreviations: ET: essential 
thrombocythemia; PV: polycythemia vera; MF: primary myelofibrosis; Hb: hemoglobin; WBC: 
white blood cell count; Plt: platelet count; sMF: secondary MF; sAML: secondary AML. Median 
values are displayed for Hb, WBC and Plt. 
C) Principal components analysis plot displaying the serum samples from 291 MPN patients 
(PC1=31.9%, PC2=16.3%) with ET (blue circles) and MF (green circles) patient samples 
positioned in distinct areas. Data are from the initial Cambridge cohort where all disease subtypes 
were collected in an unbiased fashion (ET n=146, PV n=94, PMF n=51) and normal controls 
(n=14).   
D) The right panel shows the loadings plot identifying cytokines accounting for the differences  
 
Figure 2. Elevated levels of EGF, Eotaxin, and GRO-α in patients with essential 
thrombocythemia. 
A) Serum levels of individual cytokines that are increased in patients with essential 
thrombocythemia compared to other MPN subtypes. Initial Cambridge cohort (ET n=146, PV 
n=94, MF (primary myelofibrosis) n=51) and normal controls (n=14). Boxes show medians with 
interquartile range (IQR). Mann-Whitney U-test *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
B) Peripheral blood MNCs from MPN patients were stimulated with LPS for 4 hours and GRO-α 
production measured by flow cytometry (% positive of total MNCs) (Normal controls n=3, ET=5, 
PV=10). C) Cell types producing GRO-α after LPS stimulation was evaluated using surface 
markers for T-cells, NK-cells, NKT-cells, CD56
- 
monocytes and CD56
+ monocytes (Normal 
controls n=3, ET n=5, PV n=6). The proportion of cellular sources of GRO-α in patients are 
displayed in a stacked bar graph, showing a higher frequency of GRO-α
+
CD56
+
CD14
+
 monocytes 
observed in ET patients compared to normal controls (p=0.008). 
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Figure 3. Cytokine measurements add prognostic value beyond genomics data alone. 
A) Kaplan-Meier analysis of progression-free survival according to pre-transformation levels of 
GRO-α in ET and PV patients with transformation follow-up data in initial Cam cohort (n=151). 
High levels of GRO-α correlate with increased risk of transformation from chronic phase to 
secondary MF (Cox proportional hazards modelling including age, sex and diagnosis. p=0.004). 
B) Kaplan-Meier analysis of progression-free survival in PT-1 cohort. High levels of GRO-α 
correlate with increased risk of transformation from ET to secondary MF (Cox proportional 
hazards modelling including age and sex. p=0.01). C) Variables considered in the prognostic 
model included age, sex, levels of 10 cytokines, and presence/absence of 11 driver mutations. D) 
The predictive yield (as assessed by model concordance, equivalent to the area under the curve for 
the receiver-operator characteristic) of adding cytokine quantification to prognostic models 
utilizing demographic and clinical data alone, and those additionally incorporating genomic 
variables. Genomic characterization improves the prediction for disease transformation, and 
inclusion of cytokine measurements further improve predictive power. OS = overall survival; MF-
PFS = myelofibrosis progression-free survival; and AML-PFS = AML progression-free survival 
with transformation follow-up data (n=122). E) Kaplan-Meier curve of progression-free survival 
where patients have been stratified into equally sized groups (quartiles of 30 patients each) 
according to their predicted risk as defined by a multivariate Cox proportional hazards model 
using age, GRO-α levels, IL-8 levels, IP-10 levels, and presence/absence of an SRSF2/U2AF1 
mutation (p<0.001). 
 
Figure 4. Decreases in EGF levels over time associate with MF transformation 
A) EGF levels were assessed at multiple time points during disease and patients were classified as 
having increasing, decreasing, or stable levels of EGF. EGF stability was defined as an absolute 
rate of change of <8pg/mL per year.  46% (18/39) of patients with decreased levels of EGF over 
time transformed to MF or AML, while only 24% (4/17) and 8% (2/25) of patients with stable and 
increasing levels of EGF respectively transformed to MF or AML. Dark lines indicate the point up 
until which sampling occurred and light lines indicate non-sampled follow-up. Longitudinal 
samples were taken pre- or post-transformation and are separated accordingly. B) MF progression-
free survival of patient cohorts defined by increasing, stable or decreasing EGF levels over time. 
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Patients in whom levels of EGF decreased were 4.3-fold (95% confidence interval 1.7 - 10.9) 
more likely to transform to MF or AML (p-value=0.008). 
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Supplemental Figure Legends
Figure S1. 38-cytokine screen of diagnostic serum samples from MPN patients and
healthy controls.
A) Serum concentration ypgkmLh of K3 inflammatory cytokines and chemokines across CBb
MPN patients and CC normal individualsO zars show medians for each MPN subtype ynWCC
normalG black line; nWCb/ ETG blue line; nWx+ PVG red line; nWKC MFG green linehO B)
Aomparisons of the serum levels of B selected cytokines across the three MPN subtypes and
normal individuals in the original cohortO zars show mediansO Mann-Whitney U-test cp7bObxG
ccp7bObCG cccp7bObbCG ccccp7bObbbCO
Figure S2. Serum profile of MF associated cytokines in UK and Swiss MPN cohorts.
A) TNF-? G IP-CbG and IL-3 serum levels in +BC MPN patients yC.S ETG B. PVG xC MFh from
the UK cohortO B) TNF-? G IP-CbG and IL-3 serum levels in +b. MPN patients yET nW/x PV
nW3. MF nWKKh and +. normal controls from Swiss cohortO For the Swiss cohortG samples
and clinical data were obtained in zaselG and approved by the local Ethics Aommittees yEthik
Kommission zeider zaselh and the diagnosis of MPN was established according to the
revised World Health Organization criteriaO Serum cytokine profiling in the Swiss cohort was
performed using Meso Scale Qiscovery Platform yRockvilleG MarylandG USHhO zoxes show
medians with IQRO Mann-Whitney U-test cp7bObxG ccp7bObCG cccp7bObbCG ccccp7bObbbC
Figure S3: Flow cytometry gating strategy.
Qata gating strategy used in the intracellular flow cytometry assay to identify GRO-? positive 
cells and leukocyte subsets AQxSw monocytesG AQxS- monocytesG T-cellsG NK-cellsG and 
NKT-cellsO The plots show a representative example from LPS-stimulated MNAs from a 
MPN patientO 
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